Novartis AG
NVS135.190USD
+2.620+1.98%
終値 12/15, 16:00（ET）15分遅れの株価
259.40B時価総額
18.35直近12ヶ月PER
詳細情報 Novartis AG 企業名
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Novartis AGの企業情報
企業コードNVS
会社名Novartis AG
上場日May 07, 2001
最高経営責任者「CEO」Narasimhan (Vasant)
従業員数75883
証券種類Depository Receipt
決算期末May 07
本社所在地Lichtstrasse 35
都市BASEL
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国Switzerland
郵便番号4056
電話番号41613241111
ウェブサイトhttps://www.novartis.com/
企業コードNVS
上場日May 07, 2001
最高経営責任者「CEO」Narasimhan (Vasant)
Novartis AGの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal & Compliance Officer, Member of the Executive Committee
Chief Legal & Compliance Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
他の
5.34B
38.02%
地域別USD
会社名
収益
比率
US
6.25B
44.46%
Europe
4.17B
29.67%
Asia / Africa / Australasia
2.71B
19.30%
Canada and Latin America
922.00M
6.56%
事業別
地域別
事業別USD
会社名
収益
比率
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
他の
5.34B
38.02%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
他の
97.83%
株主統計
株主統計
比率
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
他の
97.83%
種類
株主統計
比率
Investment Advisor
3.41%
Investment Advisor/Hedge Fund
2.86%
Research Firm
0.48%
Hedge Fund
0.20%
Bank and Trust
0.13%
Pension Fund
0.03%
Family Office
0.02%
他の
92.88%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
1967
135.58M
7.06%
-11.39M
2025Q2
1941
140.71M
7.27%
+2.13M
2025Q1
1953
141.07M
7.20%
+870.45K
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dodge & Cox
10.65M
0.55%
-1.17M
-9.90%
Jun 30, 2025
PRIMECAP Management Company
10.40M
0.54%
+18.55K
+0.18%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
9.06M
0.47%
+454.17K
+5.28%
Jun 30, 2025
Fisher Investments
7.12M
0.37%
+358.28K
+5.30%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
5.58M
0.29%
+78.48K
+1.43%
Jun 30, 2025
Franklin Mutual Advisers, LLC
4.16M
0.21%
-702.88K
-14.45%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.65M
0.19%
+129.18K
+3.67%
Jun 30, 2025
Parametric Portfolio Associates LLC
3.08M
0.16%
+80.38K
+2.68%
Jun 30, 2025
Managed Account Advisors LLC
2.92M
0.15%
+7.18K
+0.25%
Jun 30, 2025
Aperio Group, LLC
2.24M
0.12%
+160.56K
+7.71%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
VanEck Pharmaceutical ETF
19.83%
Amplify International Enhanced Dividend Income ETF
3.67%
Abacus FCF International Leaders ETF
3.41%
Altrius Global Dividend ETF
2.39%
Invesco International Dividend Achievers ETF
2.08%
Freedom Day Dividend ETF
2.03%
Fundamentals First ETF
1.91%
SP Funds S&P World (ex-US) ETF
1.56%
DFA Dimensional Internatl High Profitability ETF
1.54%
Avantis Responsible International Equity ETF
1.35%
詳細を見る
VanEck Pharmaceutical ETF
比率19.83%
Amplify International Enhanced Dividend Income ETF
比率3.67%
Abacus FCF International Leaders ETF
比率3.41%
Altrius Global Dividend ETF
比率2.39%
Invesco International Dividend Achievers ETF
比率2.08%
Freedom Day Dividend ETF
比率2.03%
Fundamentals First ETF
比率1.91%
SP Funds S&P World (ex-US) ETF
比率1.56%
DFA Dimensional Internatl High Profitability ETF
比率1.54%
Avantis Responsible International Equity ETF
比率1.35%
配当金
過去5年間の配当金総支払額は
36.74B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Feb 20, 2025
NVS.NB Final Cash Dividend of gross USD 3.99399 paid on Apr 25, 2025 going ex on Mar 12, 2025
Mar 12, 2025
Apr 25, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Novartis AGの上位5名の株主は誰ですか？
Novartis AGの上位5名の株主は以下のとおりです。
Dodge & Coxは10.65M株を保有しており、これは全体の0.55%に相当します。
PRIMECAP Management Companyは10.40M株を保有しており、これは全体の0.54%に相当します。
Dimensional Fund Advisors, L.P.は9.06M株を保有しており、これは全体の0.47%に相当します。
Fisher Investmentsは7.12M株を保有しており、これは全体の0.37%に相当します。
Loomis, Sayles & Company, L.P.は5.58M株を保有しており、これは全体の0.29%に相当します。
Dodge & Coxは10.65M株を保有しており、これは全体の0.55%に相当します。
PRIMECAP Management Companyは10.40M株を保有しており、これは全体の0.54%に相当します。
Dimensional Fund Advisors, L.P.は9.06M株を保有しており、これは全体の0.47%に相当します。
Fisher Investmentsは7.12M株を保有しており、これは全体の0.37%に相当します。
Loomis, Sayles & Company, L.P.は5.58M株を保有しており、これは全体の0.29%に相当します。
Novartis AGの株主タイプ上位3種は何ですか？
Novartis AGの株主タイプ上位3種は、
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
Novartis AG（NVS）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Novartis AGの株式を保有している機関は1967社あり、保有株式の総市場価値は約135.58Mで、全体の7.06%を占めています。2025Q2と比較して、機関の持ち株は-0.20%増加しています。
Novartis AGの最大の収益源は何ですか？
FY2025Q2において、Rest of portfolio部門がNovartis AGにとって最大の収益を生み出しており、その金額は2.47Bで、全収益の17.58%を占めています。
